Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TNXP
Should run today on that news.
Would not be surprised to see it break the $9 mark.
There is some selling going on now but the dips have very good so far
TNXP
Those dips have been money every time.
Thanks Bob!
BDSI
I bought the dip at 8.05 and averaged down.
Average share price now at 8.17
LBIO
Lion Biotechnologies Receives Orphan Status for Melanoma Treatment
1 hour 2 minutes ago - DJNF
By Cassandra Jaramillo
Lion Biotechnologies Inc. (LBIO) said Wednesday the U.S Food and Drug Administration granted orphan drug designation status for its treatment of malignant melanoma.
The treatment, LN-144, is the California company's lead product candidate for the treatment of Stage 2b to Stage 4 malignant melanoma. The FDA grants orphan status to drugs treating rare medical diseases, or conditions that affect fewer than 200,000 people in the U.S.
Shares of Lion recently were up 2% to $10.72.
The company, which went public in February, is developing cancer immunotherapies based on tumor-infiltrating lymphocytes, a process also known as adoptive T-cell therapy.
The FDA designation makes Lion eligible for tax credits for clinical testing, exemption from a prescription-drug user fee and seven years of market exclusivity.
Chief Executive Elma Hawkins said in a news release that the designation also will provide benefits from a regulatory and commercial perspective.
Lion is on track to initiate a Phase 2 trial of the melanoma treatment for later this year, the company said.
Yes sir!
Took my 45% profit today
Good luck to all you still holding
LBIO
Gapping up this AM
Nailed it today!!!
CUR
Nice to see it run today
Thanks!!
Thanks
What's your PT on TNXP?
I'm in here with you at $8.59
Yes
Looking good here.
What's your price target on this one?
BDSI
Added 1000 shares at 8.36 average
Buying dips
BDSI
Accumulated Friday and some this AM
Looking for a big return on this one.
PT of $15 from position average of 8.51 now!
LBIO
Was up 3% on Friday.
I hope you got some.
BDSI
Took a starter position here at the open.
CTIC
Very good volume with consolidation for the past few days.
Watch for a big move to the upside here soon.
I jumped in here today at 7.85
Looks oversold to me!
Will add on any significant weakness.
Lol
I agree!!
I sold all at just over $20 which was my price target all along.
My average PPS was $9.80 but I held all
For over 2 years from before the name change and RS.
Now I'm thinking of getting on the other side and possibly shorting it here?
Roth Capital affirms Lion Biotechnologies (NASDAQ: LBIO) at Buy with a price target of $17 after the company announced that researchers from Moffitt Cancer Center reported positive results from a pilot trial of TIL and ipilimumab in patients with metastatic melanoma.
Analyst Joseph Pantginis commented, We believe these data out of Moffitt continue to provide external validation for the TIL approach in melanoma as Lion preps the launch of its internal Phase II study with LN-144 in metastatic melanoma. Our confidence in LN-144 and the overall TIL approach remains unchanged. We are also encouraged by the data indicating higher TIL yields following a single treatment with Yervoy. This talks, in part, to Lion's approach to next generation manufacturing techniques as it looks to combination with anti-PD-1/PD-L1 blockade as a means to "pre-condition" patients. The primary focus of our investment case remains on the start of the Phase II LN-144 study in metastatic melanoma. This study represents the first internal study with TILs (supported by four positive independent Phase II programs with response rates at the 50% level). To this end, the study will target patients who are refractory to at least one systemic therapy (including Yervoy and anti-PD-1) and we believe this flexibility allows for rapid enrollment of the study. We also are especially encouraged by the planned INDs in additional solid tumors later this year, where we believe Lion differentiates itself and that CAR-T approaches can potentially falter.
LBIO
Just bought more on the dip today
Just sold CUR at 1.74 from entry at 1.55
For a nice return!
Excited to hear company overview on Thursday AM pre-market
I'm hoping that's true!!
Go TNXP!
This week should be big for:
CTIC
IMNP
Yes
You know I had been holding it for a very long time
I had a great day with HRTX and LBIO
Looking forward to next week also
Yes
Thanks for the heads up.
I'm glad I averaged down.
I'm already a nice shade of green!
Thanks!!
BTW
IMNP is teed up nicely
LBIO
Is making a move
Hope you guys are in and ready
HRTX
Hit my price target of $20
What a day!
I just bought some more an averaged down
I guess so
I started at 7.20 earlier today
LBIO
Several presentations today including the corporate presentation at 1:30
Expecting positive results here today
CUR
Just now started a position here at $1.55
Just too cheap down here to pass up.
Crazy flip:
Sold my entire position pre-market at 3.25 for a nice gain from sub-3's.
Then had to buy some back at 3.16 on the slide.
This volatility takes some stones but it's been a nice ride flipping this since $1.86
I'm buying it this morning
HRTX !!!!
Finally.
Been waiting a long time for this one.
LBIO
Upcoming dates:
Date: Friday, May 29, 2015
Panel: Immunotherapeutics: ADCs and Combination Therapies
-- BD&L, May 29, 10:20 am
Corporate Presentation: May 29, 1:30 pm
Location: Hyatt Chicago Magnificent Mile, Chicago
Jefferies 2015 Healthcare Conference
Date: Monday -- Thursday, June 1-4, 2015
Corporate Presentation: June 1, 10:00 am
Location: Grand Hyatt, New York
Its on my watch list.
Looking for an entry point in SYN